



1 February 2021

The Manager  
Company Announcements Office  
Australian Securities Exchange Limited  
20 Bridge Street  
Sydney NSW 2000

**cyclo**medica  
**techn**egas  
**ultra**lute

Cyclopharm Ltd  
ABN 74 116 931 250  
Unit 4, 1 The Crescent  
Kingsgrove NSW 2208 Australia  
T 61 2 9541 0411  
F 61 2 9543 0960  
[www.cyclopharm.com.au](http://www.cyclopharm.com.au)

### **NOTICE UNDER SECTION 708A(5) OF THE CORPORATIONS ACT 2001**

Cyclopharm Limited (the “**Company**”) is pleased to advise that it has completed a share placement (“**Placement**”) to institutional and sophisticated investors, of 11,538,462 new fully paid ordinary shares at \$2.60 per share (“**Placement Shares**”) raising A\$30.0 million before costs as announced by the Company on 25 January 2021.

An Appendix 2A in relation to the Placement is to follow.

Accordingly, the Company advises:

- 1 The Placement Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act 2001 (the “**Act**”).
- 2 As at the date of this notice, the Company has complied with:
  - (a) the provisions of Chapter 2M of the Act as they apply to the Company; and
  - (b) section 674 of the Act.
- 3 As at the date of this notice, there is no excluded information under paragraph 6(e) of section 708A of the Act which is required to be disclosed by the Company.

This ASX announcement was approved and authorised for release by James McBryer, Managing Director, CEO and Company Secretary.

#### **For more information, please contact:**

Mr James McBryer  
Managing Director, CEO and Company Secretary  
Cyclopharm Limited  
T: +61 (02) 9541 0411